Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC

Millennium Management LLC decreased its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 80.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,857 shares of the company's stock after selling 135,546 shares during the quarter. Millennium Management LLC's holdings in Compass Therapeutics were worth $49,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its position in Compass Therapeutics by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock worth $69,000 after acquiring an additional 11,326 shares during the period. Renaissance Technologies LLC lifted its position in Compass Therapeutics by 25.2% during the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock worth $404,000 after acquiring an additional 56,000 shares during the period. Barclays PLC lifted its position in Compass Therapeutics by 13.2% during the 4th quarter. Barclays PLC now owns 192,766 shares of the company's stock worth $279,000 after acquiring an additional 22,521 shares during the period. BNP Paribas Financial Markets acquired a new stake in Compass Therapeutics during the 4th quarter worth about $27,000. Finally, JPMorgan Chase & Co. lifted its position in Compass Therapeutics by 512.5% during the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after acquiring an additional 227,864 shares during the period. Institutional investors and hedge funds own 68.43% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Leerink Partnrs raised Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. D. Boral Capital reiterated a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Monday, April 28th. Piper Sandler assumed coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They set an "overweight" rating and a $12.00 price objective for the company. Wedbush reiterated an "outperform" rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Finally, Guggenheim reduced their price objective on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $13.13.

Insiders Place Their Bets

In other news, insider Jonathan Anderman acquired 20,000 shares of the business's stock in a transaction on Monday, April 7th. The stock was bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the purchase, the insider now owns 21,000 shares in the company, valued at approximately $32,340. This represents a 2,000.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is owned by company insiders.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock remained flat at $2.41 on Friday. The company had a trading volume of 746,462 shares, compared to its average volume of 954,588. Compass Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $4.08. The firm's 50-day moving average is $2.00 and its two-hundred day moving average is $2.19. The firm has a market cap of $333.26 million, a P/E ratio of -6.51 and a beta of 1.41.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). As a group, equities analysts forecast that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.